6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 18 January,2005 By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
18 JANUARY 2005


NOVOGEN RECEIVES $A1.1 MILLION ROYALTY PAYMENT FROM SOLAE LLC.

Pharmaceutical company, Novogen Limited, has received its latest
milestone royalty payment of A$1.1 million under a licence
agreement with Solae LLC (a joint venture between DuPont's
Protein Technologies International and Bunge Limited).

The companies entered the licence agreement in November 1997,
and the relevant patent applications are now at various stages
of issue around the world. Solae has the worldwide rights
(other than for Australia and New Zealand) to certain Novogen
soy isoflavone technology.

Novogen has retained all rights to its own red clover-based
isoflavone technologies. The Solae licence relates specifically
to Novogen patents or patent claims relating to soy applications.

The licence requires Solae to make regular milestone payments
and to pay royalties on sales of its products covered by the
Novogen patents.

Novogen has become one of the world's leading research and
development companies in the field of isoflavones and
human health. This knowledge has made Novogen the leader
in the related field of phenolic drugs research for novel
anti-cancer compounds.

Novogen markets the menopause health supplement Promensil
and the prostate health supplement Trinovin.

Phenoxodiol, the Company's leading anti-cancer compound,
licensed to Marshall Edwards Inc., has received
Fast Track Designation for recurrent ovarian cancer from the
Food and Drug Administration in the US.


More information on the Novogen group of companies
and their associated technology developments can be
found at www.novogen.com and at www.marshalledwardsinc.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088